Italia markets close in 7 hours 31 minutes

Novan, Inc. (NOVN)

NasdaqCM - NasdaqCM Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
2,8400-0,0900 (-3,07%)
Alla chiusura: 04:00PM EDT
2,8600 +0,02 (+0,70%)
Dopo ore: 07:13PM EDT

Novan, Inc.

4020 Stirrup Creek Drive
Suite 110
Durham, CA 27703
United States
919 485 8080
https://www.novan.com

Settore/iHealthcare
SettoreBiotechnology
Impiegati a tempo pieno29

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Ms. Paula Brown Stafford M.P.H.Pres, CEO & Chairwoman1,01MN/D1965
Mr. John M. Gay CPACFO & Corp. Sec.482,26kN/D1976
Mr. Brian M. JohnsonChief Commercial Officer443kN/D1966
Mr. John A. Donofrio Jr.Exec. VP, COO & Pres of EPI HealthN/DN/D1967
Mr. Andrew J. NovakVP of Accounting & Bus. Operations and Chief Accounting OfficerN/DN/DN/D
Dr. Carri Geer Ph.D.Sr. VP & CTON/DN/DN/D
Mr. Cole IkkalaDirector of Investor Relations, Communications & Bus. Devel.N/DN/DN/D
Mr. Stanley Hollenbach BS, J.D.Sr. VP of R&DN/DN/DN/D
Dr. Tomoko Maeda-Chubachi M.B.A., M.D., Ph.D.Chief Medical OfficerN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2021 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Novan, Inc., a pre-commercial nitric oxide-based pharmaceutical company, focuses on dermatology and anti-infective therapies. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. Novan, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Governance aziendale

L'ISS Governance QualityScore di Novan, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.